Restricted accessResearch articleFirst published online 2014-05
The Aryl Hydrocarbon Receptor Antagonist StemRegenin 1 Promotes Human Plasmacytoid and Myeloid Dendritic Cell Development from CD34 + Hematopoietic Progenitor Cells
The superiority of dendritic cells (DCs) as antigen-presenting cells has been exploited in numerous clinical trials, where generally monocyte-derived DCs (Mo-DCs) are injected to induce immunity in patients with cancer or infectious diseases. Despite promising expansion of antigen-specific T cells, the clinical responses following vaccination have been limited, indicating that further improvements of DC vaccine potency are necessary. Pre-clinical studies suggest that vaccination with combination of primary DC subsets, such as myeloid and plasmacytoid blood DCs (mDCs and pDCs, respectively), may result in stronger clinical responses. However, it is a challenge to obtain high enough numbers of primary DCs for immunotherapy, since their frequency in blood is very low. We therefore explored the possibility to generate them from hematopoietic progenitor cells (HPCs). Here, we show that by inhibiting the aryl hydrocarbon receptor with its antagonist StemRegenin 1 (SR1), clinical-scale numbers of functional BDCA2+BDCA4+ pDCs, BDCA1+ mDCs, and BDCA3+DNGR1+ mDCs can be efficiently generated from human CD34+ HPCs. The ex vivo-generated DCs were phenotypically and functionally comparable to peripheral blood DCs. They secreted high levels of pro-inflammatory cytokines such as interferon (IFN)-α, interleukin (IL)-12, and tumor necrosis factor (TNF)-α and upregulated co-stimulatory molecules and maturation markers following stimulation with Toll-like receptor (TLR) ligands. Further, they induced potent allogeneic T-cell responses and activated antigen-experienced T cells. These findings demonstrate that SR1 can be exploited to generate high numbers of functional pDCs and mDCs from CD34+ HPCs, providing an alternative option to Mo-DCs for immunotherapy of patients with cancer or infections.
Get full access to this article
View all access options for this article.
References
1.
SteinmanRM and BanchereauJ. (2007). Taking dendritic cells into medicine. Nature, 449:419–426.
2.
PaluckaK, BanchereauJ and MellmanI. (2010). Designing vaccines based on biology of human dendritic cell subsets. Immunity, 33:464–478.
3.
HilkensCM and IsaacsJD. (2013). Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?. Clin Exp Immunol, 172:148–157.
4.
FigdorCG, de VriesIJ, LesterhuisWJ and MeliefCJ. (2004). Dendritic cell immunotherapy: mapping the way. Nat Med, 10:475–480.
5.
PaluckaK and BanchereauJ. (2012). Cancer immunotherapy via dendritic cells. Nat Rev Cancer, 12:265–277.
6.
DraubeA, Klein-GonzalezN, MattheusS, BrillantC, HellmichM, EngertA and von Bergwelt-BaildonM. (2011). Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One, 6:e18801.
7.
TelJ, AarntzenEH, BabaT, SchreibeltG, SchulteBM, Benitez-RibasD, BoermanOC, CroockewitS, OyenWJ, et al. (2013). Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res, 73:1063–1075.
8.
NierkensS, den BrokMH, GarciaZ, TogherS, WagenaarsJ, WassinkM, BoonL, RuersTJ, FigdorCG, et al. (2011). Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells. Cancer Res, 71:6428–6437.
9.
IwasakiA and MedzhitovR. (2004). Toll-like receptor control of the adaptive immune responses. Nat Immunol, 5:987–995.
10.
PiccioliD, TavariniS, BorgogniE, SteriV, NutiS, SammicheliC, BardelliM, MontagnaD, LocatelliF and WackA. (2007). Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood, 109:5371–5379.
11.
LiuYJ. (2005). IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol, 23:275–306.
12.
YoneyamaH, MatsunoK, TodaE, NishiwakiT, MatsuoN, NakanoA, NarumiS, LuB, GerardC, IshikawaS and MatsushimaK. (2005). Plasmacytoid DCs help lymph node DCs to induce anti-HSV CTLs. J Exp Med, 202:425–435.
13.
PiccioliD, SammicheliC, TavariniS, NutiS, FrigimelicaE, ManettiAG, NuccitelliA, ApreaS, ValentiniS, et al. (2009). Human plasmacytoid dendritic cells are unresponsive to bacterial stimulation and require a novel type of cooperation with myeloid dendritic cells for maturation. Blood, 113:4232–4239.
14.
JounaiK, IkadoK, SugimuraT, AnoY, BraunJ and FujiwaraD. (2012). Spherical lactic acid bacteria activate plasmacytoid dendritic cells immunomodulatory function via TLR9-dependent crosstalk with myeloid dendritic cells. PLoS One, 7:e32588.
15.
LouY, LiuC, KimGJ, LiuYJ, HwuP and WangG. (2007). Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. J Immunol, 178:1534–1541.
16.
KuwajimaS, SatoT, IshidaK, TadaH, TezukaH and OhtekiT. (2006). Interleukin 15-dependent crosstalk between conventional and plasmacytoid dendritic cells is essential for CpG-induced immune activation. Nat Immunol, 7:740–746.
17.
CasadoFL, SinghKP and GasiewiczTA. (2010). The aryl hydrocarbon receptor: regulation of hematopoiesis and involvement in the progression of blood diseases. Blood Cells Mol Dis, 44:199–206.
18.
BoitanoAE, WangJ, RomeoR, BouchezLC, ParkerAE, SuttonSE, WalkerJR, FlavenyCA, PerdewGH, et al. (2010). Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science, 329:1345–1348.
19.
PlatzerB, RichterS, KneidingerD, WaltenbergerD, WoisetschlagerM and StroblH. (2009). Aryl hydrocarbon receptor activation inhibits in vitro differentiation of human monocytes and Langerhans dendritic cells. J Immunol, 183:66–74.
20.
OveresIM, de RijkeB, van Horssen-ZoetbroodA, FredrixH, de GraafAO, JansenJH, van KriekenJH, RaymakersRA, van der VoortR, de WitteTM and DolstraH. (2008). Expression of P2X5 in lymphoid malignancies results in LRH-1-specific cytotoxic T-cell-mediated lysis. Br J Haematol, 141:799–807.
21.
de RijkeB, van Horssen-ZoetbroodA, BeekmanJM, OtterudB, MaasF, WoestenenkR, KesterM, LeppertM, SchattenbergAV, et al. (2005). A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. J Clin Invest, 115:3506–3516.
22.
HoboW, BroenK, van der VeldenWJ, Greupink-DraaismaA, AdistyN, WoutersY, KesterM, FredrixH, JansenJH, et al. (2013). Association of disparities in known minor histocompatibility antigens with relapse-free survival and graft-versus-host disease after allogeneic stem cell transplantation. Biol Blood Marrow Transplant, 19:274–282.
23.
ChenW, AntonenkoS, SederstromJM, LiangX, ChanAS, KanzlerH, BlomB, BlazarBR and LiuYJ. (2004). Thrombopoietin cooperates with FLT3-ligand in the generation of plasmacytoid dendritic cell precursors from human hematopoietic progenitors. Blood, 103:2547–2553.
24.
BlomB, HoS, AntonenkoS and LiuYJ. (2000). Generation of interferon alpha-producing predendritic cell (Pre-DC)2 from human CD34(+) hematopoietic stem cells. J Exp Med, 192:1785–1796.
25.
MurrayLJ, YoungJC, OsborneLJ, LuensKM, ScollayR and HillBL. (1999). Thrombopoietin, flt3, and kit ligands together suppress apoptosis of human mobilized CD34+ cells and recruit primitive CD34+ Thy-1+ cells into rapid division. Exp Hematol, 27:1019–1028.
26.
DzionekA, FuchsA, SchmidtP, CremerS, ZyskM, MiltenyiS, BuckDW and SchmitzJ. (2000). BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol, 165:6037–6046.
27.
HemontC, NeelA, HeslanM, BraudeauC and JosienR. (2013). Human blood mDC subsets exhibit distinct TLR repertoire and responsiveness. J Leukoc Biol, 93:599–609.
28.
GuiducciC, OttG, ChanJH, DamonE, CalacsanC, MatrayT, LeeKD, CoffmanRL and BarratFJ. (2006). Properties regulating the nature of the plasmacytoid dendritic cell response to Toll-like receptor 9 activation. J Exp Med, 203:1999–2008.
29.
KerkmannM, RothenfusserS, HornungV, TowarowskiA, WagnerM, SarrisA, GieseT, EndresS and HartmannG. (2003). Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. J Immunol, 170:4465–4474.
30.
TelJ, SchreibeltG, SittigSP, MathanTS, BuschowSI, CruzLJ, LambeckAJ, FigdorCG and de VriesIJ. (2013). Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood, 121:459–467.
31.
HoeffelG, RipocheAC, MatheoudD, NascimbeniM, EscriouN, LebonP, HeshmatiF, GuilletJG, GannageM, et al. (2007). Antigen crosspresentation by human plasmacytoid dendritic cells. Immunity, 27:481–492.
32.
JoffreOP, SeguraE, SavinaA and AmigorenaS. (2012). Cross-presentation by dendritic cells. Nat Rev Immunol, 12:557–569.
33.
LiuC, LouY, LizeeG, QinH, LiuS, RabinovichB, KimGJ, WangYH, YeY, et al. (2008). Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest, 118:1165–1175.
34.
DiamondMS, KinderM, MatsushitaH, MashayekhiM, DunnGP, ArchambaultJM, LeeH, ArthurCD, WhiteJM, et al. (2011). Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med, 208:1989–2003.
35.
SalioM, PalmowskiMJ, AtzbergerA, HermansIF and CerundoloV. (2004). CpG-matured murine plasmacytoid dendritic cells are capable of in vivo priming of functional CD8 T cell responses to endogenous but not exogenous antigens. J Exp Med, 199:567–579.
36.
SchreibeltG, KlinkenbergLJ, CruzLJ, TackenPJ, TelJ, KreutzM, AdemaGJ, BrownGD, FigdorCG and de VriesIJ. (2012). The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood, 119:2284–2292.
37.
PoulinLF, SalioM, GriessingerE, Anjos-AfonsoF, CraciunL, ChenJL, KellerAM, JoffreO, ZelenayS, et al. (2010). Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med, 207:1261–1271.
38.
NizzoliG, KrietschJ, WeickA, SteinfelderS, FacciottiF, GruarinP, BiancoA, SteckelB, MoroM, et al. (2013). Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. Blood, 122:932–942.
39.
SchotteR, SchmidlinH, NagasawaM, DontjeW, KarrichJJ, UittenbogaartC, SpitsH and BlomB. (2010). Isolation and in vitro generation of gene-manipulated human plasmacytoid and conventional dendritic cells. Methods Mol Biol, 595:67–85.
40.
ProiettoAI, MittagD, RobertsAW, SpriggN and WuL. (2012). The equivalents of human blood and spleen dendritic cell subtypes can be generated in vitro from human CD34(+) stem cells in the presence of fms-like tyrosine kinase 3 ligand and thrombopoietin. Cell Mol Immunol, 9:446–454.
41.
DemoulinS, RoncaratiP, DelvenneP and HubertP. (2012). Production of large numbers of plasmacytoid dendritic cells with functional activities from CD34(+) hematopoietic progenitor cells: use of interleukin-3. Exp Hematol, 40:268–278.
42.
SpanholtzJ, PreijersF, TordoirM, TrilsbeekC, PaardekooperJ, de WitteT, SchaapN and DolstraH. (2011). Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One, 6:e20740.
43.
HoboW, NovobrantsevaTI, FredrixH, WongJ, MilsteinS, Epstein-BarashH, LiuJ, SchaapN, van der VoortR and DolstraH. (2013). Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. Cancer Immunol Immunother, 62:285–297.
44.
StevensEA, MezrichJD and BradfieldCA. (2009). The aryl hydrocarbon receptor: a perspective on potential roles in the immune system. Immunology, 127:299–311.
45.
EsserC, RannugA and StockingerB. (2009). The aryl hydrocarbon receptor in immunity. Trends Immunol, 30:447–454.
46.
NguyenNT, HaniehH, NakahamaT and KishimotoT. (2013). The roles of aryl hydrocarbon receptor in immune responses. Int Immunol, 25:335–343.
47.
SinghKP, GarrettRW, CasadoFL and GasiewiczTA. (2011). Aryl hydrocarbon receptor-null allele mice have hematopoietic stem/progenitor cells with abnormal characteristics and functions. Stem Cells Dev, 20:769–784.
48.
SchmidtJV, SuGH, ReddyJK, SimonMC and BradfieldCA. (1996). Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc Natl Acad Sci U S A, 93:6731–6736.
49.
ThurmondTS, StaplesJE, SilverstoneAE and GasiewiczTA. (2000). The aryl hydrocarbon receptor has a role in the in vivo maturation of murine bone marrow B lymphocytes and their response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicol Appl Pharmacol, 165:227–236.
50.
HirabayashiY and InoueT. (2009). Aryl hydrocarbon receptor biology and xenobiotic responses in hematopoietic progenitor cells. Biochem Pharmacol, 77:521–535.
51.
LiuH, RamachandranI and GabrilovichDI. (2013). Regulation of plasmacytoid dendritic cell development in mice by aryl hydrocarbon receptor. Immunol Cell Biol DOI: 10.1038/icb.2013.65.
52.
VorderstrasseBA and KerkvlietNI. (2001). 2,3,7,8-Tetrachlorodibenzo-p-dioxin affects the number and function of murine splenic dendritic cells and their expression of accessory molecules. Toxicol Appl Pharmacol, 171:117–125.
53.
AlbanesiC, ScarponiC, BosisioD, SozzaniS and GirolomoniG. (2010). Immune functions and recruitment of plasmacytoid dendritic cells in psoriasis. Autoimmunity, 43:215–219.
54.
KirouKA and GkrouzmanE. (2013). Anti-interferon alpha treatment in SLE. Clin Immunol, 148:303–312.
55.
RadstakeTR, van LieshoutAW, van RielPL, van den BergWB and AdemaGJ. (2005). Dendritic cells, Fc{gamma} receptors, and Toll-like receptors: potential allies in the battle against rheumatoid arthritis. Ann Rheum Dis, 64:1532–1538.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
